| Similar Articles |
|---|
 |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus.   |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
Pharmaceutical Executive
September 1, 2011 |
Filling Front and Center in the Fight against TB Dr. Mel Spigelman, President and CEO of the TB Alliance, discusses the organization's priorities in developing treatments for tuberculosis. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
December 29, 2006
Brian Lawler |
Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
Fast Company
December 2009
Erica Westly |
The Price of Winning FDA Approval Approval for a new drug or medical treatment requires extensive -- and expensive -- human trials for safety and effectiveness. |
The Motley Fool
May 9, 2007
Mike Havrilla |
Scintillating Synta Patient investors should peek at this pharma's promising pipeline. |
The Motley Fool
February 10, 2005
Charly Travers |
Focus on the Pipeline Vertex Pharmaceuticals is losing money. But it has at least one drug that makes the future look brighter. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
Bio-IT World
October 2005
Mark D. Uehling |
Phase Forward Acquires Lincoln Technologies As the most intriguing clinical trial technology deal of the year, the acquisition demonstrates both Phase Forward's financial resources and the appeal of Lincoln Technologies' Java- and Web-based tools for the analysis and visualization of drug safety. |
The Motley Fool
September 20, 2007
Brian Orelli |
Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note. |
The Motley Fool
June 29, 2007
Brian Orelli |
The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
January 12, 2005
Charly Travers |
Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity. |
Chemistry World
September 2007
Derek Lowe |
Column: In the Pipeline Will Phase Zero trials actually help drug development? |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
The Motley Fool
October 1, 2009
Brian Orelli |
Geez, Lighten Up, Mr. Market! Investors dish out undue punishment to Onyx's stock. |
The Motley Fool
December 31, 2010
Brian Orelli |
3 Biotech 2010 IPOs Worthy of a Look These IPOs are worth a spot on your watchlist. |
Pharmaceutical Executive
May 1, 2007
Waseem Noor |
Toolkit: How To Be a Better Partner Big pharmas and little biotechs have been getting hitched for years. Now it's time to add a little innovation to the relationship. Three new rules will keep the game exciting. |
The Motley Fool
March 1, 2007
Brian Lawler |
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. |
The Motley Fool
October 18, 2007
Billy Fisher |
Still Sleepless at Arena The drug company posts a wider third-quarter loss than a year ago. Investors, take note. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
March 30, 2010
Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
Bio-IT World
June 2006
Kevin Davies |
HapMap Project Prepares for Phase II Release The official release of the Phase II HapMap data will provide a publicly available trove of information on human genetic variation across populations that will reveal insights into the genetic basis of human disease and individual response to pharmaceuticals. |
Chemistry World
October 15, 2013
Dinsa Sachan |
Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed. |
The Motley Fool
October 26, 2006
Brian Lawler |
Arena Stays in the Game Despite having only early-pipeline offerings, Arena gets a boost from Cramer. More conservative investors can wait until more clinical trial results are released, since there should still be plenty of upside left in the stock if trial results are positive enough. |
The Motley Fool
May 29, 2008
Brian Lawler |
Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
March 30, 2007
Ralph Casale |
Another Genetic Sequencer Gobbled Up Roche buys out second-generation sequencer 454 Life Sciences. Investors, take note. |
The Motley Fool
July 27, 2007
Tom Taulli |
A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth. |
The Motley Fool
September 25, 2007
Brian Orelli |
No Drugs, No Rally Sonus Pharmaceuticals' lead drug fails in phase 3 trials, so the stock crashes. |
Pharmaceutical Executive
October 1, 2006
Clinton & Koroneos |
Learn & Confirm At Wyeth, a sweeping set of initiatives is transforming the R&D operation - and spotlighting a possible future for drug development. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
The Motley Fool
September 28, 2006
Brian Lawler |
Myriad Moves Forward The biotech's new cancer candidate passes phase 1 trials. Investors should take note, and make room for Myriad on their radar screens. |
The Motley Fool
September 11, 2007
Brian Orelli |
A Waiting Game for Aspreva It will be three years before Aspreva Pharmaceuticals and partner Roche evaluate results for a treatment for lupus. If and when the drug is approved, it will have to compete with a whole host of other drugs currently in trials. Investors take note. |
Pharmaceutical Executive
June 1, 2006
Sarah Houlton |
Global Report: People Problems A recent clinical trials disaster is causing UK regulators to consider revising its guidelines for Phase I human studies for biologics. However, in many cases, potential solutions present additional problems. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
The Motley Fool
October 1, 2008
Brian Orelli |
3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear. |
Chemistry World
December 1, 2014
Derek Lowe |
Progress at the pace of the slowest Chemistry is a means to an end in drug research, not an end in itself, and that can take some getting used to. It's worth thinking about where chemistry fits into the big picture. |
Bio-IT World
March 2006
Kevin Davies |
Clinical Data Launches Landmark Trial Clinical Data has launched a Phase III clinical trial for the depression drug vilazodone and will concurrently develop a diagnostic test. The study could prove to be a landmark event in pharmacogenomic medicine. |
The Motley Fool
November 14, 2011
Brian Orelli |
Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up. |
The Motley Fool
June 13, 2008
Brian Lawler |
Novo Nordisk Bleeds a Little The pharmaceutical's hot streak ends as a vital study fizzles out. |
The Motley Fool
June 5, 2009
Brian Orelli |
Failure! Merck said today that rolofylline failed to show an effect in its phase 3 clinical trial in heart failure patients. |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies. |
The Motley Fool
April 26, 2007
Tom Taulli |
Phase Forward's False Funk Ignore its stagnant shares -- new deals should continue this company's growth. |
The Motley Fool
April 19, 2004
Charly Travers |
4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
